Company: LENZ
Filing Date: 2025-04-04
Form Type: POS AM
Source: 0001628280-25-016815
Chunk: 14

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-04
Form: POS AM
Chunk 14
---
 expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include, but are not limited to, the following:

• the likelihood of our clinical trials demonstrating safety and efficacy of our product candidates to the satisfaction of the FDA, and other positive results;

• the timing, scope and likelihood of regulatory filings and approvals for LNZ100;

• our ability to obtain and maintain regulatory approval of LNZ100;

• our plans relating to the development of LNZ100;

• the size of the market opportunity for LNZ100, including our estimates of the size of the affected population and potential adoption rate;

• our plans relating to commercializing LNZ100, if approved, including the geographic areas of focus and sales strategy;

• our competitive position and the success of competing therapies that are or may become available;

• the beneficial characteristics, and the potential safety, efficacy and therapeutic effects of LNZ100;

• the need to hire additional personnel and our ability to attract and retain such personnel;

• our plans relating to the further development and manufacturing of LNZ100 and any future product candidates;

• the expected potential benefits of strategic collaborations with third parties and our ability to attract collaborators with development, regulatory and commercialization expertise;

• the rate and degree of market acceptance and clinical utility of LNZ100 and any other product candidates we may develop;

<div align='center'>7</div>

• the impact of existing laws and regulations and regulatory developments in the United States and other jurisdictions;

• our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering LNZ100, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights;

• our continued reliance on third parties to conduct any additional clinical trials of LNZ100 or any future product candidates, and for the manufacture of our product candidates for any such trials;

• the accuracy of our estimates regarding expenses